Related references
Note: Only part of the references are listed.KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab D chemotherapy vs. placebo D chemotherapy, followed by adjuvant pembrolizumab vs. placebo for earlystage TNBC
P. Schmid et al.
ANNALS OF ONCOLOGY (2021)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Julie R. Brahmer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors
Curtis R. Chong et al.
CLINICAL INFECTIOUS DISEASES (2020)
Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray
Sandra Martinez-Morilla et al.
LABORATORY INVESTIGATION (2020)
Interchangeability of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy
Emina Torlakovic et al.
MODERN PATHOLOGY (2020)
Immune-mediated adverse events following influenza vaccine in cancer patients receiving immune checkpoint inhibitors
Morgan E. Gwynn et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2020)
The Cancer Immunotherapy Biomarker Testing Landscape
Eric E. Walk et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2020)
A phase 2 clinical trialassessing theefficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer
Alice Y. Ho et al.
CANCER (2020)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Prevalence and mutational determinants of high tumor mutation burden in breast cancer
R. Barroso-Sousa et al.
ANNALS OF ONCOLOGY (2020)
Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer
S. Adams et al.
ANNALS OF ONCOLOGY (2020)
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
P. Schmid et al.
ANNALS OF ONCOLOGY (2020)
Triple-negative breast cancer-Role of immunology: A systemic review
Gizem Oner et al.
BREAST JOURNAL (2020)
Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer
Po-Han Lin et al.
CANCER SCIENCE (2020)
A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer
Romualdo Barroso-Sousa et al.
CLINICAL BREAST CANCER (2020)
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1
Preeti Narayan et al.
CLINICAL CANCER RESEARCH (2020)
Triple negative breast cancer: A thorough review of biomarkers
Jesse Lopes da Silva et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
Evidence for reducing cancer-specific mortality due to screening for breast cancer in Europe: A systematic review
Nadine Zielonke et al.
EUROPEAN JOURNAL OF CANCER (2020)
The 2019 World Health Organization classification of tumours of the breast
Puay Hoon Tan et al.
HISTOPATHOLOGY (2020)
Conception and viable twin pregnancy in a patient with metastatic melanoma while treated with CTLA-4 and PD-1 checkpoint inhibition
Amanda D. Bucheit et al.
MELANOMA RESEARCH (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
R. K. Murthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
It Is Time to Talk About Fertility and Immunotherapy
Narjust Duma et al.
ONCOLOGIST (2020)
Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: A systematic review on reporting of methods in randomized controlled trials
Stephane Faury et al.
PLOS ONE (2020)
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial
Rita Nanda et al.
JAMA ONCOLOGY (2020)
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
Flora Mulkey et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Fausto Petrelli et al.
CANCERS (2020)
PDL1/CD274 gain/amplification as a predictive marker of checkpoint blockade inhibitor efficacy in metastatic breast cancer: Exploratory analysis of the SAFIR02-IMMUNO randomized phase II trial
T. Bachelot et al.
ANNALS OF ONCOLOGY (2020)
Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple negative breast cancer
P. Schmid et al.
ANNALS OF ONCOLOGY (2020)
An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers
Ewa Przybytkowski et al.
BMC CANCER (2020)
Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer
Bharat Jasani et al.
DIAGNOSTIC PATHOLOGY (2020)
Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer
Connie Kang et al.
DRUGS (2020)
Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists
Alice Y. Ho et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
A phase II trial of nivolumab (NIVO) + palbociclib (PAL) + anastrozole (ANA) in postmenopausal women and men with estrogen receptor (ER)+/human epidermal growth factor 2 (HER2)- primary breast cancer (BC): CheckMate 7A8.
Sara M. Tolaney et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.
Javier Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119.
Eric P. Winer et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The evolving management of metastatic triple negative breast cancer
Monica K. Malhotra et al.
SEMINARS IN ONCOLOGY (2020)
Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer
Emily S. Reisenbichler et al.
MODERN PATHOLOGY (2020)
Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
Praveen Vikas et al.
FRONTIERS IN ONCOLOGY (2020)
Immuno-Oncology Biomarkers for Personalized Immunotherapy in Breast Cancer
Vida Vafaizadeh et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Tumor-infiltrating lymphocytes (TILs) in ER+/HER2-breast cancer
C. Criscitiello et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
L. A. Emens et al.
ANNALS OF ONCOLOGY (2020)
Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial
L. A. Emens et al.
ANNALS OF ONCOLOGY (2020)
Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first- line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)
D. W. Miles et al.
ANNALS OF ONCOLOGY (2020)
Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma
Raza Syed Hoda et al.
MODERN PATHOLOGY (2020)
Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm
Caroline Robert et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A. Mittendorf et al.
LANCET (2020)
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial
Sara M. Tolaney et al.
JAMA ONCOLOGY (2020)
Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis
James C. Lee et al.
SCIENCE IMMUNOLOGY (2020)
Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Lajos Pusztai et al.
CANCER RESEARCH (2020)
Imaging of tumour response to immunotherapy
Clarisse Dromain et al.
EUROPEAN RADIOLOGY EXPERIMENTAL (2020)
Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
Minetta C. Liu et al.
CANCER RESEARCH (2020)
Nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2-primary breast cancer: CheckMate 7FL
Sherene Loi et al.
CANCER RESEARCH (2020)
Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer (WJOG11418B, NEWFLAME trial)
Jun Masuda et al.
CANCER RESEARCH (2020)
Exploratory analytical harmonization of PD-L1 immunohistochemistry assays in advanced triple-negative breast cancer: A retrospective substudy of IMpassion130
Hope Rugo et al.
CANCER RESEARCH (2020)
A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze
Charles E. Geyer et al.
CANCER RESEARCH (2020)
Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer
Seung Eun Lee et al.
JOURNAL OF BREAST CANCER (2020)
A multicenter phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial
Yukinori Ozaki et al.
CANCER RESEARCH (2020)
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study
Luca Gianni et al.
CANCER RESEARCH (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive analysis from the prospective MaLife project
Norbert Marschner et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2019)
Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers
Tina Gruosso et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial
Sherene Loi et al.
LANCET ONCOLOGY (2019)
Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases
Dennis P. O'Malley et al.
MODERN PATHOLOGY (2019)
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer A Systematic Review
Michael R. Cook et al.
JAMA ONCOLOGY (2019)
Metabolic Reprogramming in Breast Cancer and Its Therapeutic Implications
Nishant Gandhi et al.
CELLS (2019)
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S. Loibl et al.
ANNALS OF ONCOLOGY (2019)
IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer
Javier Cortes et al.
FUTURE ONCOLOGY (2019)
Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1-infected.
Maria Gonzalez-Cao et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early-stage triple-negative breast cancer.
Heather L. McArthur et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.
Fatima Cardoso et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Ajjai Shivaram Alva et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?
Nina D'Abreo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Association of BRCA1-and BRCA2-deficiency with mutation burden, expression of PD-L1/ PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer
Wei Xiong Wen et al.
PLOS ONE (2019)
Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
Noha Abdel-Wahab et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features
Jonathan D. Schoenfeld et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Homologous recombination deficiency in triple negative breast cancer
Carmen Belli et al.
BREAST (2019)
Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis
Wenfa Huang et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer
Yara van Holstein et al.
DRUGS & AGING (2019)
The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population
Joobin Sattar et al.
JOURNAL OF GERIATRIC ONCOLOGY (2019)
Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
Hamzah Abu-Sbeih et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer
Audrey Simonaggio et al.
JAMA ONCOLOGY (2019)
Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis
Steve Lu et al.
JAMA ONCOLOGY (2019)
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study
Thomas S. Uldrick et al.
JAMA ONCOLOGY (2019)
Delayed immune-related events (DIRE) after discontinuation of immunotherapy: updates diagnostic hazard of autoimmunity at a distance
Marcus A. Couey et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications
Biagio Ricciuti et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies
Lindsay Angus et al.
NATURE GENETICS (2019)
A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229)
Stephen Chia et al.
ONCOLOGIST (2019)
1191OPhase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
S Domchek et al.
ANNALS OF ONCOLOGY (2019)
LBA8_PRKEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)
P Schmid et al.
ANNALS OF ONCOLOGY (2019)
Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis
A. R. Ferreira et al.
ANNALS OF ONCOLOGY (2019)
LBA21KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)
J Cortés et al.
ANNALS OF ONCOLOGY (2019)
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer A Phase 1 Study
Leisha A. Emens et al.
JAMA ONCOLOGY (2019)
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Liver-Mediated Adaptive Immune Tolerance
Meijuan Zheng et al.
FRONTIERS IN IMMUNOLOGY (2019)
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Satya Das et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system
Yinghong Zhai et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement
Apostolia M. Tsimberidou et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
If we build it they will come: targeting the immune response to breast cancer
Margaret E. Gatti-Mays et al.
NPJ BREAST CANCER (2019)
Adrenal crisis: prevention and management in adult patients
Rosemary Dineen et al.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM (2019)
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer
David B. Page et al.
NPJ BREAST CANCER (2019)
Results from KATE2, a randomized phase 2 study of atezolizumab (atezo) plus trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+advanced breast cancer (BC)
L. A. Emens et al.
CANCER RESEARCH (2019)
KEYNOTE-173: Phase 1b multicohort study of pembrolizumab (Pembro) in combination with chemotherapy as neoadjuvant treatment for triple-negative breast cancer (TNBC)
P. Schmid et al.
CANCER RESEARCH (2019)
IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab plus nab-paclitaxel in patients with treatment-naive, locally advanced or metastatic triple-negative breast cancer
L. A. Emens et al.
CANCER RESEARCH (2019)
Microsatellite instability in triple negative breast cancers
K. Kurata et al.
CANCER RESEARCH (2019)
Loss of Human Leukocyte Antigen Class I Expression Is Associated with Poor Prognosis in Patients with Advanced Breast Cancer
Hong Sik Park et al.
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE (2019)
Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER plus Breast Cancer
Andreas Heindl et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Implications of the tumor immune microenvironment for staging and therapeutics
Janis M. Taube et al.
MODERN PATHOLOGY (2018)
Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER plus Breast Cancer
Andreas Heindl et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Immune-related Adverse Events in Cancer Patients
Daniel J. Pallin et al.
ACADEMIC EMERGENCY MEDICINE (2018)
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
T. R. Cottrell et al.
ANNALS OF ONCOLOGY (2018)
Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study
Mark O'Loughlin et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy
Tricia R. Cottrell et al.
CANCER JOURNAL (2018)
Abstract OT1-01-01: IMpassion131: A phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (TNBC)
D Miles et al.
CANCER RESEARCH (2018)
Abstract OT1-02-04: SWOG S1418/NRG -BR006: A randomized, phase III trial to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple receptor-negative breast cancer with > 1 cm residual invasive cancer or positive lymph nodes (>pN1mic) after neoadjuvant chemotherapy
L Pusztai et al.
CANCER RESEARCH (2018)
Abstract OT2-07-03: IMpassion031: A phase III study comparing neoadjuvant atezolizumab vs placebo in combination with nab-paclitaxel–based chemotherapy in early triple-negative breast cancer (TNBC)
E Mittendorf et al.
CANCER RESEARCH (2018)
Abstract PD6-01: Prevalence of PDL1 and tumor infiltrating lymphocytes (TILs) in primary and metastatic TNBC
Y Li et al.
CANCER RESEARCH (2018)
It is finally time for adjuvant therapy in melanoma
S. Napolitano et al.
CANCER TREATMENT REVIEWS (2018)
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
Hope S. Rugo et al.
CLINICAL CANCER RESEARCH (2018)
Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?
Guillaume Louvel et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update
Sharon H. Giordano et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab
Susan C. Scott et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis
Peter Savas et al.
NATURE MEDICINE (2018)
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors
Aaron M. Goodman et al.
JAMA ONCOLOGY (2018)
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis
Romualdo Barroso-Sousa et al.
JAMA ONCOLOGY (2018)
Targeting adenosine for cancer immunotherapy
Robert D. Leone et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Immunological differences between primary and metastatic breast cancer
B. Szekely et al.
ANNALS OF ONCOLOGY (2018)
TOPACIO/Keynote-162: Niraparib plus pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial
Shaveta Vinayak et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2-metastatic breast cancer administered abemaciclib plus pembrolizumab.
Sara M. Tolaney et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Kathryn C. Arbour et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Gang Chen et al.
NATURE (2018)
Incidence of first and second primary cancers diagnosed among people with HIV, 1985-2013: a population-based, registry linkage study
Nancy A. Hessol et al.
LANCET HIV (2018)
Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
Alexandra Thomas et al.
ONCOIMMUNOLOGY (2018)
55PQuality of life and psychosocial needs of metastatic breast cancer patients
T Mehmood
ANNALS OF ONCOLOGY (2018)
Immune-related adverse events of immune checkpoint inhibitors: a brief review
G. Myers
CURRENT ONCOLOGY (2018)
Screening Mammography for Average-Risk Women: The Controversy and NCCN's Position
Mark A. Helvie et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Fetal Toxicity of Immunosuppressive Drugs in Pregnancy
Claudio Ponticelli et al.
JOURNAL OF CLINICAL MEDICINE (2018)
Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity
Pelagia G. Tsoutsou et al.
FRONTIERS IN ONCOLOGY (2018)
The role of neoantigen in immune checkpoint blockade therapy
Ming Yi et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2018)
Estimates of Cancer Incidence in Ethiopia in 2015 Using Population-Based Registry Data
Solomon Tessema Memirie et al.
JOURNAL OF GLOBAL ONCOLOGY (2018)
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Y. Dirix et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Breast Cancer Immunotherapy: Facts and Hopes
Leisha A. Emens
CLINICAL CANCER RESEARCH (2018)
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
A. M. Menzies et al.
ANNALS OF ONCOLOGY (2017)
Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication
Samantha Burugu et al.
BREAST CANCER (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
Jung-Min Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
Samra Turajlic et al.
LANCET ONCOLOGY (2017)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
CDK4/6 inhibition triggers anti-tumour immunity
Shom Goel et al.
NATURE (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A molecular portrait of microsatellite instability across multiple cancers
Isidro Cortes-Ciriano et al.
NATURE COMMUNICATIONS (2017)
Association of Surgical Treatment, Systemic Therapy, and Survival in Patients With Abdominal Visceral Melanoma Metastases, 1965-2014 Relevance of Surgical Cure in the Era of Modern Systemic Therapy
Gary B. Deutsch et al.
JAMA SURGERY (2017)
A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1
Patricia Gaule et al.
JAMA ONCOLOGY (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Breast Cancer and Transplantation
G. Wong et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2017)
Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review
Paola Queirolo et al.
CANCER TREATMENT REVIEWS (2017)
Genomic Evolution of Breast Cancer Metastasis and Relapse
Lucy R. Yates et al.
CANCER CELL (2017)
Phase 2 study of pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.
Sylvia Adams et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.
Sylvia Adams et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch
H. Scheerens et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2017)
Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
Alexander Faje
PITUITARY (2016)
Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer
S. Adams et al.
CANCER RESEARCH (2016)
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling
Heather L. McArthur et al.
CLINICAL CANCER RESEARCH (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
Woo Young Sun et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Classification and characterization of microsatellite instability across 18 cancer types
Ronald J. Hanse et al.
NATURE MEDICINE (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence
Justin M. Balko et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis
Xue Li et al.
TARGETED ONCOLOGY (2016)
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis
Celine Lefebvre et al.
PLOS MEDICINE (2016)
PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker
Lei Guo et al.
SPRINGERPLUS (2016)
Pseudoprogression in cancer immunotherapy: Rates, time course and patient outcomes
Vikram Kurra et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple negative breast cancer (mTNBC).
Sylvia Adams et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer
Nikita L. Mani et al.
BREAST CANCER RESEARCH (2016)
A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitorsaEuro
T. W. Chen et al.
ANNALS OF ONCOLOGY (2015)
The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant
Kobe Reynders et al.
CANCER TREATMENT REVIEWS (2015)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Hideho Okada et al.
LANCET ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer
Michael T. Barrett et al.
ONCOTARGET (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Oncofertility: a grand collaboration between reproductive medicine and oncology
Teresa K. Woodruff
REPRODUCTION (2015)
Update on the Teratogenicity of Maternal Mycophenolate Mofetil
Lisa A. Coscia et al.
JOURNAL OF PEDIATRIC GENETICS (2015)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S. Loi et al.
ANNALS OF ONCOLOGY (2014)
Targeting of two aspects of metabolism in breast cancer treatment
Bevan P. Gang et al.
CANCER BIOLOGY & THERAPY (2014)
New insights into cancer immunoediting and its three component phases elimination, equilibrium and escape
Deepak Mittal et al.
CURRENT OPINION IN IMMUNOLOGY (2014)
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
Sylvia Adams et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Effects of Screening and Systemic Adjuvant Therapy on ER-Specific US Breast Cancer Mortality
Diego Munoz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
Fabrice Andre et al.
LANCET ONCOLOGY (2014)
A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF-Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer
Gang Chen et al.
CANCER IMMUNOLOGY RESEARCH (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?
Mizuki Nishino et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
Mizuki Nishino et al.
CLINICAL CANCER RESEARCH (2013)
The cancer antigenome
Bianca Heemskerk et al.
EMBO JOURNAL (2013)
Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study
Ashley Cimino-Mathews et al.
HUMAN PATHOLOGY (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Does Chemotherapy Really Affect the Quality of Life of Women with Breast Cancer?
Sook Yeon Hwang et al.
JOURNAL OF BREAST CANCER (2013)
Drug rechallenge and treatment beyond progression-implications for drug resistance
Elizabeth A. Kuczynski et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors
Paul A. Beavis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression
Linda Sofie Lindstrom et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence
Archie Bleyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Molecular Alterations Between the Primary Breast Cancer and the Subsequent Locoregional/Metastatic Tumor
Robyn Macfarlane et al.
ONCOLOGIST (2012)
Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression
Masayuki Inoue et al.
ONCOIMMUNOLOGY (2012)
BRCA1 and BRCA2: different roles in a common pathway of genome protection
Rohini Roy et al.
NATURE REVIEWS CANCER (2012)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer
David Miles et al.
ONCOLOGIST (2011)
Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study
S. Franceschi et al.
BRITISH JOURNAL OF CANCER (2010)
Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
Robert H. Vonderheide et al.
CLINICAL CANCER RESEARCH (2010)
Role of Glucocorticoids in Breast Cancer
Jayant S. Vaidya et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Rechallenging with anthracyclines and taxanes in metastatic breast cancer
Carlo Palmieri et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer
I. H. Park et al.
ANNALS OF ONCOLOGY (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
Mary L. Disis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses
Ken M. Kunisaki et al.
LANCET INFECTIOUS DISEASES (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Trastuzumab Improves the Efficacy of Chemotherapy in Breast Cancer Treatment beyond Progression
Christina Pirvulescu et al.
BREAST CARE (2008)
PET Imaging of cancer immunotherapy
Paul C. Tunieh et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
The glucocorticoid receptor signalling in breast cancer
Paraskevi Moutsatsou et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2008)
Quality of life assessment in women with breast cancer: benefits, acceptability and utilization
Sheila Perry et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2007)
Risk of breast, ovary, and uterine corpus cancers among 85 268 women with AIDS
J. J. Goedert et al.
BRITISH JOURNAL OF CANCER (2006)
Total loss of MHC class I is an independent indicator of good prognosis in breast cancer
Z Madjd et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Effect of screening and adjuvant therapy on mortality from breast cancer
DA Berry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Epidemiology and outcomes of serious influenza-related infections in the cancer population
CD Cooksley et al.
CANCER (2005)
Quality of life among younger women with breast cancer
NE Avis et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Determinants of outcome in melanoma patients with cerebral metastases
KM Fife et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
C Sotiriou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Repeated observation of breast tumor subtypes in independent gene expression data sets
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer
D Osoba et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Microsatellite instability in early-onset breast cancer
E Ozer et al.
PATHOLOGY RESEARCH AND PRACTICE (2002)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
HER2 as a prognostic and predictive marker for breast cancer
T Cooke et al.
ANNALS OF ONCOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Microsatellite instability markers in breast cancer: A review and study showing MSI was not detected at 'BAT 25' and 'BAT 26' microsatellite markers in early-onset breast cancer
SP Siah et al.
BREAST CANCER RESEARCH AND TREATMENT (2000)
Share Paper
